Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
This study has been completed.
Sponsor:
PDL BioPharma, Inc.
Information provided by:
Facet Biotech
ClinicalTrials.gov Identifier:
NCT00109161
First received: April 22, 2005
Last updated: August 2, 2008
Last verified: August 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Estimated Study Completion Date: | October 2006 |
| Estimated Primary Completion Date: | No date given |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):